Menu

Cell Signaling in Cancer: New Targets, New Hope

The Scientist is bringing together a panel of experts to discuss their research and share insights into targeting these pathways with anti-cancer therapeutics.

May 31, 2017
The Scientist Creative Services Team

 

FREE Webinar

Thursday, June 1, 2017
2:30 - 4:00 P.M. EDT
Register Now

Communication between cancer cells has long been a target of drug-discovery efforts, but the conversations between cells can be convoluted and confused by signaling-pathway crosstalk, feedback loops, and other complex interactions. Recent advances have led to the elucidation of unexpected interactions between cells during the oncogenic transition, and these interactions are specific to the tumor microenvironment. To explore the advances in understanding cancer signaling, The Scientist is bringing together a panel of experts to discuss their research and share insights into targeting these pathways with anti-cancer therapeutics. Attendees will have the opportunity to interact with the experts, ask questions, and seek advice on topics related to their research.

Topics to be covered:

  • How the tumor microenvironment shapes tumor behavior and therapeutic efficacy
  • Signaling-pathway manipulation as a key strategy for anticancer therapies

Register Now

Meet the Speakers:

Lynne-Marie Postovit, PhD
Associate Professor, Department of Experimental Oncology
University of Alberta

 

 

 

 

William Weiss, MD, PhD
Professor, Departments of Neurology, Pediatrics, and Neurosurgery
University of California, San Francisco

 

 


 




February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.